Compare ELBM & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELBM | XLO |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.9M | 56.9M |
| IPO Year | 2022 | 2021 |
| Metric | ELBM | XLO |
|---|---|---|
| Price | $0.58 | $9.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.15 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 341.2K | 18.1K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.71 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.49 | $0.46 |
| 52 Week High | $8.70 | $9.90 |
| Indicator | ELBM | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 61.36 |
| Support Level | $0.56 | $7.47 |
| Resistance Level | $0.60 | $9.75 |
| Average True Range (ATR) | 0.04 | 0.42 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 51.97 | 62.57 |
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry. The Company's operating segments are Refinery, Exploration and Evaluation, Corporate and Other.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.